ArticleGenome biology2019
Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma.
Article in Genome biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- A Systematic Review of Common and Brain-Disease-Specific RNA Editing Alterations Providing Novel Insights into Neurological and Neurodegenerative Disease Manifestations.Biomolecules · 2022Pooled it
- ADAR2 induces the differentiation of osteosarcoma cells by editing activity on IGFBP7: new implications for therapy.Bone research · 2026Article
- Structure-aware graph learning predicts RNA editability across tissues and species.Research square · 2026Article
- Molecular Context of ADAR-Mediated Editing of Coding RNA in Colorectal and Lung Cancers.International journal of molecular sciences · 2026Article
- ADAR-GPT: A continually fine-tuned language model for predicting A-to-I RNA editing sites.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- SARS-CoV-2-induced dysregulation in ADAR editing patterns persists post viral clearance in individuals with mild COVID-19.Frontiers in cellular and infection microbiology · 2026Article
- REDInet: a temporal convolutional network-based classifier for A-to-I RNA editing detection harnessing million known events.Briefings in bioinformatics · 2025Article
- Review
- REDIportal: toward an integrated view of the A-to-I editing.Nucleic acids research · 2025Article
- Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance.Frontiers in immunology · 2025Review
- REMR: Identification of RNA Editing-mediated MiRNA Regulation in Cancers.Computational and structural biotechnology journal · 2024Article
- Bioinformatics for Inosine: Tools and Approaches to Trace This Elusive RNA Modification.Genes · 2024Review
- Increased A-to-I RNA editing in atherosclerosis and cardiomyopathies.PLoS computational biology · 2023Article
- The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome.iScience · 2022Article
- ADAR2 Protein Is Associated with Overall Survival in GBM Patients and Its Decrease Triggers the Anchorage-Independent Cell Growth Signature.Biomolecules · 2022Article
- ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide.Scientific reports · 2022Article
- Article
- ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance.The Journal of clinical investigation · 2022Article
- Landscape of adenosine-to-inosine RNA recoding across human tissues.Nature communications · 2022Article
- Epitranscriptomic Modifications Modulate Normal and Pathological Functions in CNS.Translational stroke research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenosine-to-inosine (A-to-I) RNA editing is an essential post-transcriptional mechanism mediated by ADAR enzymes that have been recently associated with cancer.
resultsHere, we characterize the inosinome signature in normal brain and de novo glioblastoma (GBM) using new metrics that re-stratify GBM patients according to their editing profiles and indicate this post-transcriptional event as a possible molecular mechanism for sexual dimorphism in GBM. We find that over 85% of de novo GBMs carry a deletion involving the genomic locus of ADAR3, which is specifically expressed in the brain. By analyzing RNA editing and patient outcomes, an intriguing gender-dependent link appears, with high editing of Alus shown to be beneficial only in male patients. We propose an inosinome-based molecular stratification of GBM patients that identifies two different GBM subgroups, INO-1 and INO-2, which can identify novel high-risk gender-specific patient groups for which more aggressive treatments may be necessary.
conclusionsOur data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future personalized targeted gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.